NASDAQ:BVXV - BIONDVAX PHARMA/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.07 -0.32 (-5.94 %) (As of 02/22/2019 04:00 PM ET)Previous Close$5.07Today's Range$5.00 - $5.1052-Week Range$3.51 - $6.93Volume29,079 shsAverage Volume2,210 shsMarket Capitalization$33.11 millionP/E Ratio-2.56Dividend YieldN/ABeta1.22 ProfileDiscussionChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel. Receive BVXV News and Ratings via Email Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BVXV Previous Symbol CUSIPN/A CIK1611747 Webwww.biondvax.com Phone972-8930-2529Debt Debt-to-Equity Ratio2.95 Current Ratio20.74 Quick Ratio20.74Price-To-Earnings Trailing P/E Ratio-2.56 Forward P/E Ratio-101.40 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book2.04Profitability EPS (Most Recent Fiscal Year)($1.98) Net Income$-9,960,000.00 Net MarginsN/A Return on Equity-168.28% Return on Assets-74.56%Miscellaneous Employees14 Outstanding Shares6,530,000Market Cap$33.11 million Next Earnings Date4/29/2019 (Estimated) OptionableNot Optionable BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions What is BIONDVAX PHARMA/S's stock symbol? BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV." When is BIONDVAX PHARMA/S's next earnings date? BIONDVAX PHARMA/S is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for BIONDVAX PHARMA/S. Has BIONDVAX PHARMA/S been receiving favorable news coverage? Media stories about BVXV stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BIONDVAX PHARMA/S earned a news impact score of -1.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near term. Who are some of BIONDVAX PHARMA/S's key competitors? Some companies that are related to BIONDVAX PHARMA/S include Surface Oncology (SURF), Pluristem Therapeutics (PSTI), Outlook Therapeutics (OTLK), Champions Oncology (CSBR), Nantkwest (NK), Idera Pharmaceuticals (IDRA), Brainstorm Cell Therapeutics (BCLI), INmune Bio (INMB), Aptose Biosciences (APTO), Cidara Therapeutics (CDTX), Applied Genetic Technologies (AGTC), AVITA MED LTD/S (AVMXY), BioCardia (BCDA), Proteon Therapeutics (PRTO) and Oncobiologics (ONS). What other stocks do shareholders of BIONDVAX PHARMA/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIONDVAX PHARMA/S investors own include Exelixis (EXEL), Gilead Sciences (GILD), AbbVie (ABBV), Agilent Technologies (A), Teva Pharmaceutical Industries (TEVA), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), Novavax (NVAX), Blackstone Group (BX) and Neurocrine Biosciences (NBIX). Who are BIONDVAX PHARMA/S's key executives? BIONDVAX PHARMA/S's management team includes the folowing people: Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 57)Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49)Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 55)Dr. Shimon Hassin, Chief Operating OfficerMr. Elad Mark, Head of Site & Process Devel. When did BIONDVAX PHARMA/S IPO? (BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO. How do I buy shares of BIONDVAX PHARMA/S? Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BIONDVAX PHARMA/S's stock price today? One share of BVXV stock can currently be purchased for approximately $5.07. How big of a company is BIONDVAX PHARMA/S? BIONDVAX PHARMA/S has a market capitalization of $33.11 million. The company earns $-9,960,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe. What is BIONDVAX PHARMA/S's official website? The official website for BIONDVAX PHARMA/S is http://www.biondvax.com. How can I contact BIONDVAX PHARMA/S? BIONDVAX PHARMA/S's mailing address is 14 Einstein Street, Nes Ziona L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected] MarketBeat Community Rating for BIONDVAX PHARMA/S (NASDAQ BVXV)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 102 (Vote Outperform)Underperform Votes: 113 (Vote Underperform)Total Votes: 215MarketBeat's community ratings are surveys of what our community members think about BIONDVAX PHARMA/S and other stocks. Vote "Outperform" if you believe BVXV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?